Patients will be monitored in the clinic for thirty minutes post -immunization for the development of any adverse effects. The immunization s will be supervised by a nurse or physician that has completed a Pediatric Ad vanced Life Support (PALS) course. A cardiac resuscitation cart will be available in the immediate vicinity when performing these immunizations in case of severe allergic reactions. The three vaccines will each be given 2 + 1 week(s) apart. Subjects who will not receive xALT either due to failure of the product to meet release criteria or inability to manufacture a viable product, may receive additional DC vaccination(s) if more than 3 doses were initially generated. Subsequent DC vaccination will begin 4 weeks (+/ - 5 days) after vaccine number 3 and continue every 4 weeks (+/ - 5 days) until all doses have been exhausted, the subject meets a withdrawal endpoint, or the treating physician elects to stop further vaccination. These subjects will be evaluated for toxicity and laboratory immune measures; however, they will be replaced for the purposes of efficacy assessments . Patients will be monitored clinically with routine physical and neurologic examinations at every visit and with a contrasted -enhanced CT or MRI every 8 + 4 weeks. Peripheral blood will be obtained bimonthly , if feasible, until progression as well as outlined in the study flow sheet below for immunologic monitoring. 16.2 TTRNA-xALT Administration Patients will receive a single dose of TTRNA -xALT consisting of autologous lymphocytes enriched for tumor -specific lymphocytes after in vitro stimulation with TTRNA -pulsed DCs on the same day as the first DC vaccination. No further TTRNA -xALT administrations will be given. TTRNA -xALT infusions will be Re-MATC H Protocol Page 63 of 106 Version: 20180628 administered at the main site and the patients will be monitored by an RN during and for 1 hour following the procedure. If any patient develops signs of infection or is febrile prior to the infusion it wil l be postponed pending clinical work -up. The TTRNA -xALT product will be prepared , delivered, and administered according to Standard Operating Procedures. Subject identifiers will be double -verified prior to TTRNA -xALT administration as is standard BMT tra nsfusion procedure. The patient will be pre -medicated 30 -60 minutes prior to infusion with acetaminophen ( up to 10- 15 mg/kg/dose) and Benadryl ( up to 1 mg/kg) to reduce infusion- related reactions. All patients will have a n intravenous catheter placed duri ng PBSCT or one will be placed for the procedure. The TTRNA -xALT will be infused in accordance with SOP -UFBTIP -132. Vital signs will be assessed prior to and post infusion then every 15 minutes for 1 hour. The infusion will last 10 -30 minutes depending on volume to be infused. The Infusion and any adverse experiences will be documented on SDW -UFBTIP -003. All other institutional transfusion and cell infusion policies will be followed.